News
More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.
More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.
Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.
13h
News-Medical.Net on MSNOne RSV shot cuts severe lung infections in older adults for three seasons, trial showsA phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...
Outbreaks of vaccine-preventable diseases such as measles, meningitis, and yellow fever are on the rise globally amid ...
22h
MyChesCo on MSNExpanded Recommendation for GSK’s AREXVY Vaccine Targets Adults at Higher Risk for Severe RSVThe Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results